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Comparative Study of Influenza Virus Replication in MDCK Cells and
in Primary Cells Derived from Adenoids and Airway Epithelium
Natalia A. Ilyushina,a Mine R. Ikizler,b Yoshihiro Kawaoka,c,d,e Larisa G. Rudenko,f John J. Treanor,g Kanta Subbarao,h
and Peter F. Wrighta
Department of Pediatrics, Geisel Medical School at Dartmouth, Lebanon, New Hampshire, USAa; Department of Pediatrics, Vanderbilt University School of Medicine,
Nashville, Tennessee, USAb; Departments of Microbiology and Immunology and of Special Pathogens, Institute of Medical Sciences, University of Tokyo, Tokyo, Japanc;
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USAd; ERATO Infection-Induced Host
Responses Project, Japan Science and Technology Agency, Saitama, Japane; Department of Virology, Institute of Experimental Medicine RAMS, St. Petersburg, Russiaf;
Department of Microbiology and Immunology, Division of Infectious Diseases, University of Rochester, Rochester, New York, USAg; and Laboratory of Infectious Diseases,
NIAID, NIH, Bethesda, Maryland, USAh
Although clinical trials with human subjects are essential for determination of safety, infectivity, and immunogenicity, it is de-
sirable to know in advance the infectiousness of potential candidate live attenuated influenza vaccine strains for human use. We
compared the replication kinetics of wild-type and live attenuated influenza viruses, including H1N1, H3N2, H9N2, and B
strains, in Madin-Darby canine kidney (MDCK) cells, primary epithelial cells derived from human adenoids, and human bron-
chial epithelium (NHBE cells). Our data showed that despite the fact that all tissue culture models lack a functional adaptive im-
mune system, differentiated cultures of human epithelium exhibited the greatest restriction for all H1N1, H3N2, and B vaccine
viruses studied among three cell types tested and the best correlation with their levels of attenuation seen in clinical trials with
humans. In contrast, the data obtained with MDCK cells were the least predictive of restricted viral replication of live attenuated
vaccine viruses in humans. We were able to detect a statistically significant difference between the replication abilities of the U.S.
(A/Ann Arbor/6/60) and Russian (A/Leningrad/134/17/57) cold-adapted vaccine donor strains in NHBE cultures. Since live at-
tenuated pandemic influenza vaccines may potentially express a hemagglutinin and neuraminidase from a non-human influenza
virus, we assessed which of the three cell cultures could be used to optimally evaluate the infectivity and cellular tropism of vi-
ruses derived from different hosts. Among the three cell types tested, NHBE cultures most adequately reflected the infectivity
and cellular tropism of influenza virus strains with different receptor specificities. NHBE cultures could be considered for use as
a screening step for evaluating the restricted replication of influenza vaccine candidates.
Influenza A and B viruses infect 5 to 15% of the global populationannually and cause an estimated 250,000 to 500,000 deaths (35,
54). Outbreaks and epidemics of influenza virus regularly cause
excess mortality among the elderly and considerable morbidity in
all ages during the influenza season (32, 35). Vaccination is the
most effective way of preventing disease caused by influenza vi-
ruses. Since influenza A and B viruses undergo continuous anti-
genic change, the influenza vaccine components often need to be
updated annually to antigenically match the circulating strains.
The two influenza vaccines currently licensed in the United States
are the inactivated trivalent influenza vaccine, given by intramus-
cular injection, and the live attenuated influenza vaccine, admin-
istered intranasally (30, 35). It is recognized that live attenuated
influenza virus vaccines are more efficacious than inactivated vac-
cines in young children (1–3, 5, 8, 38) and that both vaccines could
afford protection with differing efficacy against drifted strains in
adults (4, 8, 27, 33, 36).
Live attenuated influenza virus vaccine contains hemaggluti-
nin (HA) and neuraminidase (NA) gene segments from the three
currently circulating influenza strains (H1N1, H3N2, and B) and
the six internal protein gene segments (PB1, PB2, PA, NP, M, and
NS) from master donor A and B viruses (21, 30). Donor strains
were independently developed by sequential passages at lower
temperature (25°C) in the United States and the former Soviet
Union from virulent H2N2 and B isolates (A/Ann Arbor/6/60 and
B/Ann Arbor/1/66, respectively, in the United States and A/Len-
ingrad/134/57 and B/USSR/60/69, respectively, in the former So-
viet Union) (20, 51). Two influenza A virus donor strains were
prepared in Russia: A/Leningrad/134/17/57 (H2N2), the “17
passaged” variant of the master strain, for use in adults and A/Len-
ingrad/134/47/57 (H2N2), the “47 passaged” variant of the
same parent (which received an extra 30 passages at low temper-
atures), for use in children (15, 20). Both influenza A and B donor
viruses are cold adapted (ca) (replicate efficiently at 25°C and
33°C), temperature sensitive (ts) (do not replicate at temperatures
above 39°C), and attenuated (att) (do not produce classic influ-
enza-like illness and are restricted in replication in the lower re-
spiratory tracts of ferrets) (22, 30). These specific phenotypes, me-
diated by mutations in the internal gene segments (15, 17, 20, 30),
lead to limited replication in the respiratory tract of the infected
host and stimulate both systemic and cellular immune responses
(30, 42, 54). The ca U.S. and Russian master donor strains have
not been directly compared for infectivity, immunogenicity, and
safety in clinical trials with humans.
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As live attenuated influenza vaccines replicate in the nasophar-
ynx of the recipient, infectious vaccine virus can be cultured from
upper respiratory tract secretions after vaccination, a phenome-
non termed “virus shedding.” Previous studies have estimated the
median human infectious dose required for infection with live
attenuated seasonal influenza vaccine to be 2.5 to 4.5 log10 50%
tissue culture infective doses (TCID50) in seronegative children
and 5.0 to 6.4 log10 TCID50 in seronegative adults (12, 31, 42, 49).
There is a direct correlation between the magnitude of shedding of
influenza virus and the illness experienced by the host (30). There-
fore, for reasons of safety, infectivity, and immunogenicity, it is
desirable to know in advance the levels of replication of potential
candidate live attenuated vaccine strains for human use.
In addition to yearly outbreaks and epidemics, influenza A
viruses cause periodic pandemics, in which viruses containing
novel HA and/or NA are introduced into susceptible human pop-
ulations (54). In preparation for the next influenza pandemic, a
number of strategies to develop pandemic vaccines are under way,
including the use of live attenuated vaccines. Unfortunately, it is
hard to predict the levels of replication in humans of candidate
vaccines bearing HA influenza virus subtypes with pandemic po-
tential (H2, H5, H7, and H9 HA subtypes) before performing
human clinical trials (45). The replication of such attenuated vac-
cine strains in mice and ferrets is not predictive of replication of
these viruses in humans. For example, H5N1 and H9N2 ca vaccine
strains replicated minimally in humans but were readily recovered
by culture in small-animal models (9, 18, 19, 47). The reasons for
this discrepancy are not completely understood, but it may be
related to (i) preexisting antibodies to HAs and/or NAs in human
serum that cross-react with the avian HAs and/or NAs and de-
crease virus vaccine replication, (ii) cellular immunity, or (iii)
decreased affinity of the avian HAs for sialic acid (SA) receptors in
the human upper airways (44). Human influenza virus HAs pref-
erentially bind to cell surface receptors terminating in SA 2,6-
galactose (SA2,6Gal), whereas avian influenza viruses preferen-
tially bind to receptors terminating in SA2,3Gal (39, 44). Thus,
new screening tools or models that predict the infectivity of ca
influenza viruses in the human host need to be developed.
In the present study, we compared the replication kinetics of
wild-type (wt) and ca influenza viruses, including H1N1,
H3N2, H9N2, and B strains, in Madin-Darby canine kidney
(MDCK) cells and human epithelial cells derived from ade-
noids (HAEC cells) and bronchial epithelium (NHBE cells).
We also compared the replication abilities of the U.S. (ca
A/Ann Arbor/6/60 [H2N2]) and three Russian (ca A/Lenin-
grad/134/17/57 [H2N2], ca A/Leningrad/134/47/57 [H2N2],
and ca A/Leningrad/134/80/57 [H2N2]) vaccine donor strains
side by side in MDCK and NHBE cells. Since live attenuated
influenza vaccines could potentially bear HA and NA genes of
different origin (human, avian, swine, or equine), we also as-
sessed which of the three cell cultures could optimally evaluate
the infectivity and cellular tropism of influenza viruses from
different hosts and with different receptor specificities.
MATERIALS AND METHODS
Cells. MDCK cells were obtained from the American Type Culture Col-
lection (Manassas, VA) and were maintained as described elsewhere (16).
Primary NHBE cells from human tracheal/bronchial tissues were ob-
tained from Lonza (Walkersville, MD). Cells of passage 2 were grown on
membrane supports (6.5-mm Transwell; Corning Inc., Corning, NY) at
the air-liquid interface in serum-free and hormone- and growth factor-
supplemented medium as described previously (16, 25). Fully differenti-
ated 4- to 8-week-old cultures were used for all experiments.
Adenoids were obtained at the time of adenoidectomy performed for
independently defined clinical indications under a protocol approved by
the Vanderbilt Institutional Review Board (Nashville, TN). The isolation
and growth of primary epithelial cells from adenoidal tissue (HAEC cells)
were previously described (13, 53). Briefly, optimal recovery of viable
epithelial cells was obtained by placing the whole tissue in minimal essen-
tial medium with 0.1% pronase type 14 (Sigma Chemicals, St. Louis, MO)
and antibiotics and rocking overnight at 4°C. The superficial layers of cells
were further dispersed by pipetting, and cells were placed in medium
containing 10% fetal calf serum to inactivate the pronase. The cells were
then centrifuged, resuspended in 50% Ham’s F-12 medium (Mediatech
Inc., Manassas, VA)–50% Eagle’s minimal essential medium with supple-
ments (insulin, 5 g/ml; transferrin, 5 g/ml; epidermal growth factor, 10
ng/ml; cholera toxin, 10 ng/ml; hydrocortisone, 106 M; bovine hypotha-
lamic extract, 15 g/ml; HEPES buffer, 0.015 M; retinol, 107 M; genta-
micin, 50 g/ml; penicillin G, 15 U/ml; streptomycin, 15 U/ml; and fetal
calf serum, 0.5%) and seeded on 24-well tissue culture plates coated with
a collagen matrix of Vitrogen 100 (Cohesion, Palo Alto, CA). The cells
were incubated at 37°C under 5% CO2 until they reached 90% confluence.
Virus isolates. The wt and ca A/California/10/78 (H1N1), A/Alaska/
6/77 (H3N2), A/Washington/897/80 (H3N2), and ca A/Ann Arbor/6/60
(H2N2) influenza viruses were kindly provided by Kanta Subbarao at the
National Institute of Allergy and Infectious Diseases, Bethesda, MD. The
wt and ca A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2),
A/Wyoming/03/03 (H3N2), B/Hong Kong/330/01, and ca A/chicken/
HK/G9/97 (H9N2) influenza viruses were obtained from the Influenza
Division of the Centers for Disease Control and Prevention, Atlanta, GA.
The wt A/Leningrad/134/57 (H2N2), ca A/Leningrad/134/17/57 (H2N2),
ca A/Leningrad/134/47/57 (H2N2), and ca A/Leningrad/134/80/57
(H2N2) viruses were obtained from the Institute for Experimental Med-
icine, Russian Academy of Medical Science, St. Petersburg, Russia. Hu-
man (A/Tottori/849/94 AL3 [H3N2], A/Tottori/849/94 K4 [H3N2],
A/Tottori/872/94 AL3 [H3N2]), avian (A/duck/Ukraine/1/63 [H3N8],
A/duck/Hokkaido/8/80 [H3N8]), equine (A/equine/TN/5/86 [H3N8]),
and swine (A/swine/Italy/635/87 [H3N2]) strains were kindly provided by
Yoshihiro Kawaoka at the University of Wisconsin, Madison, WI. Stock
viruses were prepared by one passage in the allantoic cavities of 10-day-
old embryonated chicken eggs for 48 h at 37°C (or at 33°C for ca and B
viruses), and aliquots were stored at 70°C until used. All experimental
work was performed in a biosafety level 2 laboratory approved for use with
these strains by the U.S. Department of Agriculture and the U.S. Centers
for Disease Control and Prevention.
Infectivities of influenza viruses. The infectivities of H1N1, H2N2,
H3N2, and H3N8 influenza A and influenza B viruses were determined as
PFU/ml in MDCK cells. All the viruses were titrated in MDCK cells due to
inability to plaque in other cell culture models despite the fact that the use
of MDCK cells for determining infectious titers could be regarded as a
potential confounding factor of this study. Briefly, confluent MDCK cells
were incubated at 37°C (or at 33°C for wt and ca reassortant viruses) for 1
h with 10-fold serial dilutions of virus. The cells were then washed and
overlaid with minimal essential medium containing 1 g/ml L-(tosyl-
amido-2-phenyl)ethylchloromethylketone (TPCK)-treated trypsin, 0.3%
bovine serum albumin (BSA), and 0.9% Bacto agar. After 3 days of incu-
bation at 37°C (or 33°C), cells were stained with 0.1% crystal violet in 10%
formaldehyde solution, and the PFU per milliliter were determined.
The infectivity of ca A/chicken/HK/G9/97 (H9N2) virus was defined
as log10 50% tissue culture infective dose (TCID50) as described previously
(16), because this H9N2 virus did not produce plaques in MDCK cells.
Briefly, confluent monolayers of MDCK cultures growing in 96-well
plates were inoculated with serial virus dilutions (each dilution was added
to five wells) in the presence of 1 g/ml TPCK-treated trypsin. After 3
days, virus was titrated by hemagglutination assay, and virus titers were
Ilyushina et al.
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expressed as log10TCID50/ml by the endpoint method of Reed and
Muench (40).
Replication kinetics. To determine multistep growth curves, HAEC
and MDCK cells were infected with viruses at an identical multiplicity of
infection (MOI) of 0.01 PFU/cell at 33°C. After 1 h of incubation, the cells
were washed and overlaid with infection medium (minimal essential me-
dium with 0.3% BSA); 1 g/ml TPCK-treated trypsin was added only in
MDCK cells, because HAEC cells support the growth of influenza viruses
without exogenous trypsin (13). Supernatants were collected at 1, 24, 48,
and 72 h postinfection and stored at 70°C for titration by plaque assay.
To determine multistep growth curves in NHBE cells, triplicate cell
cultures growing in 6.5-mm-diameter inserts were washed extensively
with sterile phosphate-buffered saline (PBS) to remove mucus secretions
on the apical surface prior to infection and then were inoculated via the
apical side with each influenza virus at an MOI of 0.01 at 33°C. After 1 h of
incubation, the inoculum was removed. Viruses released into the apical
compartment of NHBE cells were harvested at the indicated time points
by the apical addition and collection of 300 l of medium allowed to
equilibrate for 30 min at 33°C. The virus titers were determined as log10
PFU/ml in MDCK cells.
The area under the curve (AUC) viral load was defined as the area
under the multistep growth curve and calculated by the trapezoidal rule,
using exact viral titers at 24, 48, and 72 h postinfection as determined by
plaque assay in MDCK cells.
Immunostaining and light microscopy. MDCK and NHBE cells were
infected with H3 human, avian, swine, and equine viruses at an MOI of
0.01 and fixed for 30 min in 4% formaldehyde at 8 and 24 h postinfection.
Fixed cultures were permeabilized with 0.5% Triton X-100, blocked with
3% BSA, and stained with mouse anti-NP IgG diluted in 3% BSA in PBS.
After a 1-h incubation, the cells were then incubated with goat horseradish
peroxidase (HRP)-labeled anti-mouse IgG (Sigma-Aldrich, St. Louis,
MO). For localization of ciliated cells, fixed NHBE cells were costained
with anti--tubulin IV antibody and HRP-labeled secondary antibody for
detection. The cultures were mounted using Crystal Mount (Biomeda,
Foster City, CA).
For cell counting, the cultures were observed en face by using a Nikon
microscope at 40 and 100 objectives. In microscopic fields, the per-
centage of infected cells with respect to the total number of cells was
calculated. In NHBE cells, the percentage of ciliated infected cells with
respect to the total number of infected cells was also calculated. For each
sample, 20 fields were analyzed and the results were averaged.
Receptor-binding assay. The binding of H3 influenza viruses to fetuin
(containing 2,3- and 2,6-linked sialyl receptors) was measured in a
direct solid-phase assay using the immobilized virus and horseradish per-
oxidase-conjugated fetuin, as described previously (14). The affinity of
viruses for synthetic 3=- and 6=-sialylglycopolymers obtained by conjuga-
tion of a 1-N-glycyl derivative of 3=- or 6=-sialyllactose (3=SL or 6=SL) or a
3-aminopropylglycoside of 3=- or 6=-sialyllactosamine (3=SLN or 6=SLN)
with poly(4-phenylacrylate) (7) was measured in a competitive assay
based on the inhibition of binding to peroxidase-labeled fetuin (24).
3=SLN and 6=SLN-acrylic polymers contain an additional amino group
compared to 3=SL or 6=SL and more closely approximate “avian-type” or
“human-type” sialyl receptors, respectively (26). Association constant
(Ka) values were determined as the sialic acid (Neu5Ac) concentration at
the point Amax/2 on Scatchard plots.
Statistical analysis. The virus yields, AUCs, mean peak viral titers, and
binding to sialyl receptors of influenza A and B viruses were compared
either by analysis of variance (ANOVA) or by use of an unpaired t test. A
probability value of 0.05 was prospectively chosen to indicate that the
findings were not the result of chance alone.
RESULTS
Replication kinetics of wt and ca A/California/10/78 (H1N1),
A/Alaska/6/77 (H3N2), and A/Washington/897/80 (H3N2) in-
fluenza viruses in HAEC, MDCK, and NHBE cells. To assess
which cell culture system could be used to adequately evaluate the
viral growth of attenuated vaccine candidates, we first determined
the levels of replication of early ca live influenza A virus vaccine
strains, i.e., ca A/California/10/78 (H1N1), ca A/Alaska/6/77
(H3N2), and ca A/Washington/897/80 (H3N2) reassortants, in
comparison with their respective wt viruses in HAEC, MDCK, and
NHBE cells (Fig. 1; Table 1). Viral replication was compared by
inoculating all three cultures with the wt and ca viruses at an MOI
of 0.01 at 33°C and determining yields of the viral progeny at 1, 24,
FIG 1 Replication kinetics of wt and ca A/California/10/78 (H1N1), A/Alaska/
6/77 (H3N2), and A/Washington/897/80 (H3N2) influenza viruses in HAEC
(A), MDCK (B), and NHBE (C) cell cultures. Cultures were infected with
viruses at an MOI of 0.01 PFU/cell at 33°C. Supernatants were collected at 1,
24, 48, and 72 h postinfection, and the virus titers were determined as log10
PFU/ml in MDCK cells. *, P  0.05; °, P  0.01 (compared with the value for
the respective wt virus, determined with an unpaired t test).
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48, and 72 h postinfection by plaque titration in MDCK cells. The
growth of influenza viruses was supplemented by the addition of
trypsin in MDCK cells, whereas no proteolytic enzymes were
added to the epithelial cell systems.
Our data showed that wt A/California/10/78 (H1N1), wt
A/Alaska/6/77 (H3N2), and wt A/Washington/897/80 (H3N2)
replicated to the same extent in each cell line tested, as seen by
similar total amounts of viral load (AUC) and almost equal peak
viral titers (Table 1). All wt strains grew to significantly higher
titers than the respective ca viruses at 48 and 72 h after infection in
HAEC, MDCK, and NHBE cells (1.2 to 6.8 log units; P  0.01)
(Fig. 1). The replication abilities of the ca reassortant viruses (i.e.,
AUCs, peak viral titers, and virus yields at each time point) dif-
fered significantly (P  0.05) from each other in HAEC and NHBE
cells but not in MDCK cells (Fig. 1; Table 1).
We further performed pairwise comparisons of the cumulative
amounts of each virus and peak viral titers in the three cell types
(see Table S1 in the supplemental material). The levels of replica-
tion of the wt and ca viruses together with the levels of decrease of
replication of the ca viruses were almost always significantly dif-
ferent in the three cell culture systems. The most limited growth of
both wt and ca viruses was observed in HAEC cells (P  0.05).
Overall, our parallel experiments demonstrated that all three ca
reassortants, i.e., ca A/California/10/78 (H1N1), ca A/Alaska/6/77
(H3N2), and ca A/Washington/897/80 (H3N2), exhibited the
most attenuated growth in NHBE cells (i.e., decreases of viral peak
titers were 5.7, 2.2, and 2.6 log units in comparison to the respec-
tive wt viruses, respectively) (Table 1).
Replication kinetics of wt and ca A/New Caledonia/20/99
(H1N1), A/Panama/2007/99 (H3N2), and A/Wyoming/03/03
(H3N2) influenza viruses in MDCK and NHBE cells. We evalu-
ated the replication abilities of more contemporary ca influenza A
virus vaccine strains, i.e., ca A/New Caledonia/20/99 (H1N1), ca
A/Panama/2007/99 (H3N2), and ca A/Wyoming/03/03 (H3N2),
in comparison with their respective wt viruses in MDCK and
NHBE cells (Fig. 2; Table 2). We observed that two wt H3N2
viruses, wt A/Panama/2007/99 and wt A/Wyoming/03/03, repli-
cated similarly (i.e., no significantly different AUCs, peak viral
titers, or virus yields were observed) and to significantly higher
titers than wt A/New Caledonia/20/99 (H1N1) at 24, 48, and 72 h
after infection in both cell types (1.6 to 3.4 log units; P  0.01).
The replication kinetics of two ca H3N2 reassortant viruses, ca
A/Panama/2007/99 and ca A/Wyoming/03/03, did not differ sig-
nificantly from each other (Fig. 2) or between the two cell systems
(see Table S1 in the supplemental material). They replicated to
significantly lower titers than the respective wt viruses at 24, 48,
and 72 h after infection in MDCK and NHBE cells (3.2 to 6.7 log
units; P  0.01) (Fig. 2). Notably, ca A/New Caledonia/20/99
(H1N1) virus replicated to a significantly higher extent than the
respective wt virus and the two other ca H3N2 reassortants in
MDCK cells, as seen by its significantly higher AUCs, peak viral
titers, and virus yields in this cell line (P  0.01) (Table 2). In
contrast, ca A/New Caledonia/20/99 (H1N1) virus exhibited a vi-
ral load similar to those of ca H3N2 viruses ca A/Panama/2007/99
and ca A/Wyoming/03/03 and significantly limited growth with a
decrease of peak viral titer of 1.9 log units (P  0.01) in compar-
ison to the respective wt virus in NHBE cells (Fig. 2; Table 2).
Taken together, our experiments clearly showed that differenti-
ated NHBE cultures exhibited the greatest restriction for all stud-
FIG 2 Replication kinetics of wt and ca A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), and A/Wyoming/03/03 (H3N2) influenza vi-
ruses in MDCK (A) and NHBE (B) cell cultures. Cultures were infected with
viruses at an MOI of 0.01 PFU/cell at 33°C. Supernatants were collected at 1,
24, 48, and 72 h postinfection, and the virus titers were determined as log10
PFU/ml in MDCK cells. *, P  0.05; °, P  0.01 (compared with the value for
the respective wt virus, determined with an unpaired t test).
TABLE 1 Areas under the curve and mean peak viral titers for wt and ca
A/California/10/78, A/Alaska/6/77, and A/Washington/897/80 influenza
viruses in HAEC, MDCK, and NHBE cell cultures
Virus Subtype




wt H1N1 223.6 (5.9) 364.8 (7.8) 301.8 (8.6)
ca H1N1 28.8 (1.4) 266.7 (5.7) 53.0 (2.9)
Degree of restrictionb 194.8 (4.5) 98.1 (2.1) 248.8 (5.7)
A/Alaska/6/77
wt H3N2 244.0 (5.9) 362.5 (7.7) 372.1 (8.2)
ca H3N2 170.3 (4.6) 246.7 (5.6) 258.2 (6.0)
Degree of restriction 73.7 (1.3) 115.8 (2.1) 113.9 (2.2)
A/Washington/897/80
wt H3N2 229.1 (5.7) 362.5 (7.6) 324.6 (7.7)
ca H3N2 129.7 (3.2) 290.5 (6.2) 143.6 (5.1)
Degree of restriction 99.4 (2.5) 72.0 (1.4) 181.0 (2.6)
a The area under the curve (AUC) represents the total viral load at 24, 48, and 72 h
postinfection.
b The degree of restriction of viral replication is expressed as the value for wt virus
minus the value for the corresponding ca virus.
Ilyushina et al.
11728 jvi.asm.org Journal of Virology
ied ca H1N1 and H3N2 vaccine viruses among three cell types
tested.
Comparison of replication kinetics of U.S. and Russian ca
influenza vaccine donor strains in MDCK and NHBE cells. Since
there is a correlation between the level of replication of influenza
virus and its capacity to induce immunity (30), we compared side
by side the replication abilities of different ca H2N2 vaccine donor
strains, i.e., ca A/Ann Arbor/6/60, ca A/Leningrad/134/17/57, and
ca A/Leningrad/134/47/57, in MDCK and NHBE cells (Fig. 3; Ta-
ble 3). wt A/Leningrad/134/57 (H2N2) and its “80 passaged”
variant ca A/Leningrad/134/80/57 (H2N2) were also included in
the comparison. In MDCK cells, we observed that although ca
A/Leningrad/134/17/57 and ca A/Leningrad/134/47/57 exhibited
significantly higher peak viral titers and virus yields than wt
A/Leningrad/134/57 and ca A/Leningrad/134/80/57 at 24, 48, and
72 h after infection (0.6 log units; P  0.01) (Fig. 3A), all four
strains shed similar amount of virus (Table 3). In NHBE cells, wt
A/Leningrad/134/57 and ca A/Leningrad/134/17/57 replicated
similarly, whereas ca A/Leningrad/134/47/57 and ca A/Leningrad/
134/80/57 showed significantly lower peak viral titers and virus
yields at 24, 48, and 72 h after infection (0.7 to 2.9 log units; P 
0.05) (Fig. 3B). ca A/Leningrad/134/80/57 (H2N2) virus repli-
cated to a significantly lower extent, as seen by AUC, than the
respective wt strain (P  0.01) (Table 3), which was consistent
with its higher in vitro passage history.
We further evaluated the replication abilities of the Russian
influenza A vaccine donor strains in comparison with the U.S.
donor strain, ca A/Ann Arbor/6/60 (H2N2), in MDCK and NHBE
cells (Fig. 3; Table 3). We did not observe significantly different
AUCs for all the viruses in MDCK cells; however, wt A/Leningrad/
134/57 (H2N2) and its “80 passaged” ca A/Leningrad/134/80/57
(H2N2) variant exhibited significantly lower peak viral titers and
virus yields at 24, 48, and 72 h after infection than ca A/Ann Arbor/
6/60 in this cell line (0.7 log units; P  0.05). In NHBE cells, the
replication kinetics of ca A/Ann Arbor/6/60 and ca A/Leningrad/
134/80/57 did not differ from each other (as seen by similar AUCs
and peak viral titers) (Table 3). However, wt A/Leningrad/134/57,
ca A/Leningrad/134/17/57, and ca A/Leningrad/134/47/57 grew to
significantly higher titers at 48 and 72 h after infection than ca
A/Ann Arbor/6/60 (1.8 to 4.3 log units; P  0.01) (Fig. 3B) and
shed significantly larger amounts of virus (P  0.01) (Table 3).
Taken together, our data showed statistically significant differ-
ences between the replication abilities of the U.S. and Russian ca
vaccine donor strains in NHBE cells.
Replication kinetics of influenza viruses isolated from differ-
ent species in HAEC, MDCK, and NHBE cells. In this study, we
assessed which of the three cell culture models could reflect the
load of human infection based on the source (host) of the virus.
For this purpose, we chose seven viruses of the H3 HA subtype
that were isolated from different animal species, i.e., humans,
birds, pigs, and horses, and assayed their yields after multiple rep-
lication cycles in HAEC, MDCK, and NHBE cultures (Fig. 4). Our
results demonstrated no statistically significant difference be-
tween the replication kinetics of all the strains in HAEC and
MDCK cells (Fig. 4A and B). Human, avian, swine, and equine
isolates replicated to titers of 104.1 to 8.8 PFU/ml, suggesting that
these two cell lines were totally susceptible to influenza viruses of
FIG 3 Replication kinetics of ca A/Ann Arbor/6/60, wt A/Leningrad/134/57,
ca A/Leningrad/134/17/57, ca A/Leningrad/134/47/57, and ca A/Leningrad/
134/80/57 influenza viruses in MDCK (A) and NHBE (B) cell cultures. Cul-
tures were infected with viruses at an MOI of 0.01 PFU/cell at 33°C. Superna-
tants were collected at 1, 24, 48, and 72 h postinfection, and the virus titers were
determined as log10 PFU/ml in MDCK cells. *, P  0.05; °, P  0.01 (compared
with the value for wt A/Leningrad/134/57 virus, determined by one-way
ANOVA for Russian strains only).
TABLE 2 Areas under the curve and mean peak viral titers for wt and ca
A/New Caledonia/20/99, A/Panama/2007/99, and A/Wyoming/03/03
influenza viruses in MDCK and NHBE cell cultures
Virus Subtype






wt H1N1 239.5 (5.2) 340.8 (7.5)
ca H1N1 351.8 (8.5) 201.2 (5.6)
Degree of restrictionb 112.3 (3.1) 139.6 (1.9)
A/Panama/2007/99
wt H3N2 352.2 (8.6) 429.9 (9.1)
ca H3N2 180.7 (4.1) 130.9 (2.9)
Degree of restriction 171.5 (4.5) 299.0 (6.2)
A/Wyoming/03/03
wt H3N2 368.6 (7.9) 443.8 (9.6)
ca H3N2 166.2 (3.7) 137.1 (3.0)
Degree of restriction 202.4 (4.3) 306.7 (6.6)
a The area under the curve (AUC) represents the total viral load at 24, 48, and 72 h
postinfection. Bold indicates an increase in titer and lack of restricted replication of ca
influenza vaccine virus.
b The degree of restriction of viral replication is expressed as the value for wt virus
minus the value for the corresponding ca virus.
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different origin and, therefore, could not predict the risk of hu-
man infection (Table 4). In contrast, we observed three different
patterns of replication corresponding to the origin of influenza
virus in NHBE cells (Fig. 4C). (i)Three human isolates, A/Tottori/
849/94 (H3N2) AL3, A/Tottori/849/94 (H3N2) K4, and A/Tot-
tori/872/94 (H3N2) AL3, grew to significantly higher titers (1.0 to
8.0 log units higher; P  0.05) than the rest of the viruses. (ii) The
replication abilities of the avian viruses, A/duck/Ukraine/1/63
(H3N8) and A/duck/Hokkaido/8/80 (H3N8), did not differ from
that of the swine A/swine/Italy/635/87 (H3N2) virus, and the
yields of avian and swine isolates were approximately 66% of those
of the human viruses at 24, 48, and 72 h after infection. (iii) The
equine A/equine/TN/5/86 (H3N8) isolate exhibited the least rep-
lication in NHBE cells (mean peak titer of 1.2 log10 PFU/ml) (Fig.
4C; Table 4), indicating that this virus possessed minimal infec-
tivity compared to the other viruses tested. Statistically significant
differences between cumulative amounts of viral load and mean
peak viral titers of human versus equine versus avian and swine
isolates were observed in NHBE but not in HAEC or MDCK cells
(P  0.01; Table 4).
Cellular tropism and virus spread of influenza viruses iso-
lated from different species in HAEC, MDCK, and NHBE cells.
To determine why NHBE cultures are capable of reflecting the
capacity of influenza strains to infect humans, we further assessed
cell-specific tropism of influenza viruses of different origin in
NHBE and MDCK cells. We infected two cell lines with either
virus at an MOI of 0.01, fixed the cells at 8 h postinfection (i.e.,
after the first cycle of viral replication), and then immunostained
the cultures for viral antigen (Table 4). The patterns of infection
with H3 influenza virus strains of different origin were strikingly
different between cell lines. All viruses were able to infect MDCK
cells in the presence of trypsin, with significantly different capac-
ities (P  0.05). These data suggested that human, avian, swine,
and equine viruses possessed no host range limitation in this cell
line. In contrast, in NHBE cells at 8 h postinfection, only three
human isolates, A/Tottori/849/94 (H3N2) AL3, A/Tottori/849/94
(H3N2) K4, and A/Tottori/872/94 (H3N2) AL3, showed replica-
tion (Table 4), suggesting that these viruses from the human host
possess better tropism for NHBE cells than avian, swine, and
equine isolates.
We further compared patterns of virus spread by H3 influenza
viruses of different origin at 24 h after viral inoculation. Human,
avian, and swine strains infected all cells in MDCK monolayers,
and equine isolate A/equine/TN/5/86 (H3N8) infected 53% of
TABLE 3 Areas under the curve and mean peak viral titers for ca A/Ann
Arbor/6/60, wt A/Leningrad/134/57, ca A/Leningrad/134/17/57, ca A/
Leningrad/134/47/57, and ca A/Leningrad/134/80/57 influenza viruses
in MDCK and NHBE cell cultures
Virus Subtype





ca A/Ann Arbor/6/60 H2N2 344.7 (7.3) 165.5 (4.2)
wt A/Leningrad/134/57 H2N2 310.8 (6.6c) 326.2c (7.2c)
ca A/Leningrad/134/17/57 H2N2 346.8 (7.3) 318.9c (7.2c)
Degree of restrictionb 36.0 (0.7) 7.3 (0)
ca A/Leningrad/134/47/57 H2N2 337.7 (7.1) 277.6c (6.6c)
Degree of restriction 26.9 (0.5) 48.6 (0.6)
ca A/Leningrad/134/80/57 H2N2 313.8 (6.7c) 214.7 (5.1)
Degree of restriction 3.0 (0.1) 111.5 (2.1)
a The area under the curve (AUC) represents the total viral load at 24, 48, and 72 h
postinfection. Bold indicates an increase in titer and lack of restricted replication of ca
influenza vaccine virus.
b The degree of restriction of viral replication is expressed as the value for wt virus
minus the value for the corresponding ca virus.
c P  0.01 compared with the value for ca A/Ann Arbor/6/60 (H2N2) virus, by one-way
ANOVA.
FIG 4 Replication kinetics of H3 human, avian, swine, and equine influenza A
viruses in HAEC (A), MDCK (B), and NHBE (C) cell cultures. Cultures were
infected with viruses at an MOI of 0.01 PFU/cell. Supernatants were collected
at the indicated time points and titrated in MDCK cells by plaque assay. Rep-
resentative results expressed as log10 PFU/ml from 3 independent experiments
are shown.
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all the cells (Table 4). In contrast, limited growth and the focal
nature of the influenza infection were observed in NHBE cultures.
After infection (24 h), human viruses A/Tottori/849/94 (H3N2)
AL3, A/Tottori/849/94 (H3N2) K4, and A/Tottori/872/94
(H3N2) AL3 infected 7-fold more cells than avian and swine
strains (Table 4). In addition, human isolates produced continu-
ous foci of infected cells, which included both nonciliated and
ciliated (46%) (data not shown) cells. Avian viruses A/duck/
Ukraine/1/63 (H3N8) and A/duck/Hokkaido/8/80 (H3N8) in-
fected the same amount of cells as the swine A/swine/Italy/635/87
(H3N2) virus (1.5%) (Table 3), and most of the infected cells
were ciliated (65%) (data not shown). The equine A/equine/TN/
5/86 (H3N8) isolate exhibited negligible infection in NHBE cells
(Table 4). Taken together, our results suggested that NHBE cell
cultures could approximate the cellular tropism of influenza vi-
ruses isolated from different species to the human respiratory
tract.
Receptor specificity of H3 influenza A viruses isolated from
different species. To examine whether the observed cellular tro-
pism and virus spread of influenza viruses of different origin in
NHBE cells were mediated by the receptor specificity of the viral
HA, we measured the receptor specificities of the H3 influenza
virus isolates to synthetic sialic substrates (3=SL/N and 6=SL/N)
(Fig. 5). As shown by the Ka values, human viruses A/Tottori/
849/94 (H3N2) AL3, A/Tottori/849/94 K4, and A/Tottori/872/94
(H3N2) AL3 exhibited increased affinity for 6=SL/N (synthetic
sialosaccharides with the “human-type” SA2,6Gal linkage),
whereas the binding to the “avian-type” 3= substrates 3=SL/N was
negligible. A similar pattern was observed for the swine A/swine/
Italy/635/87 (H3N2) virus. Two avian H3 viruses, A/duck/
Ukraine/1/63 (H3N8) and A/duck/Hokkaido/8/80 (H3N8), and
one equine isolate, A/equine/TN/5/86 (H3N8), bound strongly to
3=SL only (Fig. 5). Therefore, our experiments showed that differ-
ential cell tropism and virus spread of H3 influenza viruses iso-
lated from different species were dependent, but only partially, on
HA receptor specificity in NHBE cells.
Replication kinetics of ca A/chicken/HK/G9/97 (H9N2) and
wt and ca B/Hong Kong/330/01 influenza viruses in MDCK and
NHBE cells. Live attenuated A/Ann Arbor/6/60 ca influenza vac-
cines have been made with HA influenza subtypes with pandemic
potential (H2, H5, H7, and H9 HA subtypes). The replication of
such vaccine strains in mice and ferrets has not been predictive of
replication of these viruses in humans (18, 19, 45, 46). Therefore,
we assessed the growth capacity of the ca H9N2 pandemic vaccine
strain, ca A/chicken/HK/G9/97, in MDCK and NHBE cells. We
observed that the level of replication of ca A/chicken/HK/G9/97
(H9N2) was significantly different in the two cell culture systems
(Table 5; see Table S1 in the supplemental material). In MDCK
cells, ca H9N2 virus replicated to a significantly higher extent than
other ca H1N1 and H3N2 reassortants studied, as seen by its sig-
nificantly higher AUC (P  0.01) (Tables 1, 2, and 5). In contrast,
ca A/chicken/HK/G9/97 (H9N2) exhibited a viral load similar to
those of other ca viruses, except ca A/California/10/78 (H1N1)
(P  0.01) (Table 1) and ca A/Panama/2007/99 (H3N2) (P 
0.05) (Table 2), in NHBE cultures. We observed significantly dif-
ferent peak viral titers of all studied ca vaccine strains in MDCK
cells (P  0.05). Conversely, no statistically significant difference
was found between peak viral titers of ca reassortants, except ca
A/Alaska/6/77 (H3N2), in NHBE cells (P  0.05) (Tables 1, 2,
and 5).
Finally, we assessed whether the NHBE culture model could
adequately reflect the restriction of replication of the ca live influ-
enza B virus vaccine strain, ca B/Hong Kong/330/01, in compari-
son with the respective wt B/Hong Kong/330/01 virus. Both iso-
lates replicated to titers of 103.5 PFU/ml in MDCK cells, showing
no statistically significant difference between their replication ki-
netics in this cell line (Table 5). In contrast, wt and ca B viruses
TABLE 4 Areas under the curve, mean peak viral titers, and cell tropism of H3 influenza viruses isolated from different hosts in HAEC, MDCK, and
NHBE cell cultures
Virus Subtype
AUC,a mean  SD (mean peak viral titer, log10 PFU/ml)
% of infected cells at 8 h (24 h) postinfection,
mean  SDb
HAEC MDCK NHBE MDCK NHBE
A/Tottori/849/94 AL3 H3N2 262.4  6.2 (5.6) 263.9  6.2 (5.9) 359.8  11.0 (7.7) 9.5  2.3 (100) 0.9  0.4 (8.1  2.6)
A/Tottori/849/94 K4 H3N2 263.9  13.0 (6.1) 360.0  17.2 (8.0) 390.2  27.2 (8.4) 3.5  0.1 (100) 0.5  0.2 (9.3  3.4)
A/Tottori/872/94 AL3 H3N2 311.5  26.6 (6.8) 396.2  26.6 (8.8) 379.1  19.4 (8.1) 3.9  1.3 (100) 0.6  0.3 (7.3  5.5)
A/duck/Ukraine/1/63 H3N8 222.7  16.1 (5.0) 283.2  16.1 (6.5) 227.7  25.7 (5.7) 2.3  0.4 (100) 0.01 (1.3  0.7)
A/duck/Hokkaido/8/80 H3N8 176.7  19.2 (4.1) 326.4  19.2 (7.2) 275.2  11.4 (6.5) 6.0  0.7 (100) 0.01 (2.6  0.8)
A/equine/TN/5/86 H3N8 194.2  11.6 (4.9) 272.3  11.6 (5.7) 29.5  31.6 (1.2) 1.1  0.4 (53.0  19.9) 0.01 (0.07)
A/swine/Italy/635/87 H3N2 293.2  18.6 (7.0) 275.5  18.6 (7.0) 259.5  30.7 (5.9) 3.7  0.9 (100) 0.01 (0.7  0.5)
a The area under the curve (AUC) represents the total viral load at 24, 48, and 72 h postinfection.
b MDCK, HAEC, and NHBE cells were infected with H3 influenza viruses of different origins at an MOI of 0.01. Due to similar results being observed in MDCK and HAEC cells,
data for HAEC cells are not shown.
FIG 5 Receptor specificities of H3 human, avian, swine, and equine influenza
A viruses. Association constants (Ka) of virus complexes with synthetic sialyl-
glycopolymers conjugated to 3=SL(N) and 6=SL(N) are shown. Higher Ka val-
ues indicate stronger binding. Values are the means  standard deviations
(SD) from 4 independent experiments.
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replicated to significantly different titers at 24, 48, and 72 h after
infection in NHBE cells (2.0-log-unit difference; P  0.01) (data
not shown). The ca B/Hong Kong/330/01 strain exhibited signif-
icantly limited growth, with a decrease of peak viral titer of 1.9 log
unit (P  0.01) compared to that of the wt virus in the epithelial
cells (Table 5). Therefore, our experiments showed that differen-
tiated NHBE cultures could reflect the restricted replication of ca
influenza B viruses in humans.
DISCUSSION
We compared the replication kinetics of ca live attenuated vaccine
candidates, including H1N1, H3N2, and B strains, in comparison
with their respective wt viruses in MDCK cells, human adenoid
epithelial cells, and bronchial airway epithelium to assess which
cell culture model could more consistently and accurately reflect
their infectivities in humans. Since the levels of replication of sev-
eral wt and ca influenza A virus strains used in this study have been
previously evaluated in clinical trials with adult and seronegative
pediatric volunteers (10, 11, 28, 29), we were able to compare their
viral growth in humans and three tissue culture systems. Previous
studies demonstrated that three ca reassortant viruses, ca A/Cali-
fornia/10/78 (H1N1), ca A/Alaska/6/77 (H3N2), and ca A/Wash-
ington/897/80 (H3N2), exhibited different degrees of attenuation
(	3.9, 	4.5, and 2.8 log units, respectively), as measured by
comparison of mean peak viral titers (log10 TCID50/ml of naso-
pharyngeal wash sample) between the wt and ca viruses adminis-
tered at similar doses to humans (10, 28, 29). Unfortunately, we
were unable to determine any significant correlation by Spear-
man’s rank correlation analysis (P 	 0.05) between degrees of
restriction of ca A/California/10/78 (H1N1), ca A/Alaska/6/77
(H3N2), and ca A/Washington/897/80 (H3N2) strains in humans
and those in any of the cell culture systems tested. However, our
data demonstrated that the levels of attenuation of these three ca
viruses in human subjects were consistently higher (2.8 logs)
(10, 28–30) than those in MDCK cells. Furthermore, the ca A/New
Caledonia/20/99 (H1N1) reassortant replicated to significantly
higher viral titers than the respective wt H1N1 virus (P  0.01),
and no statistically significant difference was observed between
the replication abilities of wt and ca B/Hong Kong/330/01 viruses
in MDCK cells. Taking these findings together, we can speculate
that data obtained in MDCK cells could be the least predictive of
restricted viral replication of ca live attenuated vaccine viruses in
humans.
In this study, we observed that limited growth of ca vaccine
viruses was reflected in HAEC and NHBE cultures. However,
HAEC cells remain very difficult to grow and could vary between
different donors, whereas the two other cell types studied are com-
mercially available and therefore could be used from the same
source/donor for different experiments. Our experiments showed
that differentiated NHBE cultures exhibited a consistently greater
restriction for all studied ca H1N1, H3N2, and B vaccine viruses
among the three cell lines tested. A similar pattern was observed
for ca A/California/10/78 (H1N1) virus in NHBE cells isolated
from a different human donor (data not shown). Despite the fact
that all tissue culture models lack a functional adaptive immune
system, which would obviously play a role in virus replication in
the host, NHBE cells exhibited the best correlation between the
degrees of restriction of viral replication of ca A/California/10/78
(H1N1), ca A/Alaska/6/77 (H3N2), and ca A/Washington/897/80
(H3N2) and those seen in clinical trials with humans (10, 28–30).
ca A/New Caledonia/20/99 (H1N1), ca A/Panama/2007/99
(H3N2), and ca A/Wyoming/03/03 (H3N2) showed the lowest
virus yields in NHBE cells, which were in good correlation with
recently published data (6, 23). Therefore, NHBE cells may be
considered for use as the screening step for evaluating the re-
stricted replication phenotype of potential influenza virus vaccine
candidates in humans.
There has been a long-standing parallel development in Russia
of potential live attenuated vaccines (20, 51). To date, there are no
reports of side-by-side comparisons of the U.S. and Russian ca
H2N2 vaccine donor strains, ca A/Ann Arbor/6/60, ca A/Lenin-
grad/134/17/57, and ca A/Leningrad/134/47/57, in cell culture
models or in humans. So far, in only one study were immune
responses to these donor strains in the lungs and mediastinal
lymph nodes of mice compared (52). Overall, combined data for
viral clearance, antibody-secreting cells, and cytokine responses
suggested that ca A/Leningrad/134/17/57 is a superior immuno-
gen to ca A/Leningrad/134/47/57, which in turn is superior to ca
A/Ann Arbor/6/60 (52). In addition, two reassortant vaccines pre-
pared from the ca A/Ann Arbor/6/60 and ca A/Leningrad/134/
17/57 donor strains with the surface antigens of A/Korea/1/82
(H3N2) were compared in rats, ferrets, and humans (34). A reas-
sortant prepared from the Russian strain induced slightly better
rates of seroconversion, but conclusions as to their relative immu-
nogenicities could not be made because of differences in the num-
ber of internal genes present in each reassortant. Here, for the first
time, we compared side by side the replication abilities of the U.S.
and Russian ca H2N2 vaccine donor strains in two cell lines,
MDCK and NHBE cells. We did not observe statistically signifi-
cant differences in replication kinetics of these viruses (as seen by
similar AUCs, viral peak titers, and virus yields at all time points)
in MDCK cells. In contrast, a statistically significant difference
between the replication abilities of the U.S. and Russian ca vaccine
donor strains was detected in NHBE cultures (P  0.05). ca
A/Leningrad/134/17/57, which has become the main vaccine do-
nor strain in Russia, replicated to significantly higher titers (1
TABLE 5 Areas under the curve and mean peak viral titers of ca
A/Chicken/HK/G9/97 and wt and ca B/Hong Kong/330/01 influenza
viruses in MDCK and NHBE cell cultures
Virus Subtype





ca A/chicken/HK/G9/97 H9N2 443.2 (7.1) 216.6 (3.8)
B/Hong Kong/330/01
wt 218.2 (3.3) 342.8 (5.4)
ca 235.0 (3.7) 217.1c (3.5d)
Degree of restrictionb 16.8 (0.4) 125.7 (1.9)
a The area under the curve (AUC) represents total viral load at 24, 48, and 72 h
postinfection. ca A/chicken/HK/G9/97 (H9N2) influenza virus did not produce plaques
in MDCK cells; these values are defined as log10 TCID50/ml  SD determined in
MDCK cells after 3 days of incubation at 33°C with 10-fold serially diluted virus. Bold
indicates an increase in titer and lack of restricted replication of ca influenza vaccine
virus.
b The degree of restriction of viral replication was expressed as the value for wt virus
minus the value for the corresponding ca virus.
c P  0.05 compared with the value for wt B/Hong Kong/330/01 virus, determined with
an unpaired t test.
d P  0.01 compared with the value for wt B/Hong Kong/330/01 virus, determined with
an unpaired t test.
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log unit; P  0.05) than ca A/Leningrad/134/47/57, which in turn
replicated to significantly higher titers (2.7 log units; P  0.01)
than ca A/Ann Arbor/6/60 at 48 and 72 h after infection in human
airway epithelium. Therefore, we observed that NHBE cultures
were able to rank the levels of replication of various ca live atten-
uated influenza vaccines compared to each other. This property
can assist in choosing the ca vaccine donor strain with the appro-
priate balance between replicative capacity and lack of reactoge-
nicity.
For use in pandemic preparedness, live attenuated influenza
vaccines will likely need to represent novel HA and NA genes from
different species (45, 46). In this study, we assessed whether NHBE
cultures could reflect the ability of an animal influenza virus to
infect humans. Taking into account that previous studies demon-
strated transmission of avian and swine viruses to humans (41)
but that horse-to-human transmission remains to be reported
(48), we can speculate that the pattern of virus infectivity of the
studied H3 influenza viruses from different species of origin (i.e.,
human, avian, swine, and equine) in NHBE cells could parallel the
pattern of infectivity of these strains in humans.
Our results also showed that NHBE cell cultures most ade-
quately approximated the cellular tropism of influenza viruses
isolated from different species to the human respiratory tract. Pre-
vious studies have suggested that airway epithelial cell cultures
contain ciliated, nonciliated, and goblet cells. Although both types
of receptors (SA2,6 and SA2,3) are present on the cell surface in
NHBE cultures (as they are in HAEC cultures [43]), NHBE cul-
tures express abundantly more SA2,6, while SA2,3 is expressed
at a lower level (25, 37). It was shown that SA2,6 receptor moi-
eties were abundant on the apical surface of nonciliated cells and
were particularly concentrated on the microvilli. However, a
lower level of SA2,6 was also observed on the apical surface of
some ciliated and goblet cells (37, 50), suggesting that 2,6-linked
SA is distributed across all cell types in NHBE cultures. “Avian-
type” SA2,3 receptors were shown to be predominant on the
apical surface of most, but not all ciliated cells at the base of the
cilial shaft in the region of microvilli and were also found to a
much lesser degree on some nonciliated cells (25, 50). Taken to-
gether, our experiments showed that differential cell tropism and
virus spread of human and avian influenza isolates were depen-
dent, but only partially, on HA receptor specificity. However, our
data also demonstrated that despite the fact that both human and
swine viruses exhibited human-like virus receptor specificity, only
human viruses replicated to a higher extent in NHBE cells. Among
H3 viruses of different origin with avian-like receptor specificity,
only avian and not equine strains were able to establish some
limited infection in human airway epithelium. Overall, possible
explanations for the more limited growth of the avian, swine, and
equine strains compared to the human viruses could be innate
immunity and some unknown host range mechanisms that are
present in NHBE cells but not in MDCK or HAEC cells.
Finally, in this study we assessed the replication ability of the ca
A/chicken/HK/G9/97 (H9N2) pandemic vaccine strain, which
contained avian surface glycoproteins and was tested in a clinical
trial in humans (18), in MDCK and NHBE cells. We compared its
replication with those of human ca H1N1 and H3N2 vaccine
strains in an attempt to explain the robust difference seen in rep-
lication between seasonal and avian ca influenza vaccines in
healthy adult volunteers (9, 18, 19, 45, 46). The ca H9N2 virus
replicated similarly to other classical ca reassortants and exhibited
similar viral titers in NHBE cultures. However, the degree of re-
striction differed from that observed in the clinical trial in humans
(18). We can speculate that although NHBE cultures are able to
reflect the restricted phenotype of ca influenza vaccine viruses, the
lack of replication of the avian ca H9N2 vaccine virus seen in
adults (18), but not in the NHBE cell model, suggests the presence
of host immune factors in humans that induce innate and hetero-
subtypic protection against infection with avian ca vaccines. Such
heterosubtypic immunity could be conferred by previous infec-
tion with influenza viruses belonging to another HA subtypes and
appears to be enough to restrict to some extent the replication of
human ca vaccines as well (10, 28, 29).
In conclusion, in the present study we compared three tissue
culture systems, i.e., HAEC, MDCK, and NHBE cells, for their
ability to model the levels of restriction of ca influenza vaccine
viruses and the risk of infection and cellular tropism of influenza
strains of different origin with different receptor specificities. Our
data showed that differentiated cultures of human airway epithe-
lium exhibited the best approximation to the events in humans.
Although clinical trials with human subjects are essential, NHBE
cultures could be considered for use as a screening step for evalu-
ating and possibly ranking the restricted replication of influenza
vaccine candidates having HA proteins of different origin.
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